Subtype
Endometrial Neoplasm
CI-CAN-00007648Explore in graph →
Non-malignant400 active trials4 approved drugs28 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007648Explore in graph →
Clinical trials
1,340 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04152018 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | terminated | Phase 1 | 85 | PfizerINDUSTRY | 5 | May 28, 2025 | clinicaltrials |
| NCT03508570 | Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis | completed | Phase 1 | 26 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT05067972 | A Study of PF-07260437 in Advanced or Metastatic Solid Tumors(C4431001) | terminated | Phase 1 | 30 | PfizerINDUSTRY | 2 | May 6, 2025 | clinicaltrials |
| NCT02632448 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | completed | Phase 1 / Phase 2 | 229 | Esperas Pharma Inc.OTHER | 4 | May 2, 2025 | clinicaltrials |
| NCT04514692 | Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging | terminated | Phase 1 / Phase 2 | 7 | Stanford UniversityOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT04706962 | TH1902 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 70 | TheratechnologiesINDUSTRY | 2 | Apr 15, 2025 | clinicaltrials |
| NCT04925284 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | completed | Phase 1 | 269 | ExelixisINDUSTRY | 9 | Apr 4, 2025 | clinicaltrials |
| NCT06385548 | Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer(LiDer) | withdrawn | Phase 1 / Phase 2 | 0 | Vall d'Hebron Institute of OncologyOTHER | 0 | Apr 1, 2025 | clinicaltrials |
| NCT02922764 | A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer | completed | Phase 1 | 146 | Inspirna, Inc.INDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT04196257 | BP1001-A in Patients With Advanced or Recurrent Solid Tumors | recruiting | Phase 1 | 50 | Bio-Path Holdings, Inc.INDUSTRY | 1 | Mar 7, 2025 | clinicaltrials |
| NCT03552471 | Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer | completed | Phase 1 | 25 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT05669430 | A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 365 | GV20 TherapeuticsINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT05229900 | A Study of SGN-ALPV in Advanced Solid Tumors | terminated | Phase 1 | 43 | Seagen Inc.INDUSTRY | 5 | Feb 10, 2025 | clinicaltrials |
| NCT04665921 | A Study of SGN-STNV in Advanced Solid Tumors | terminated | Phase 1 | 111 | Seagen Inc.INDUSTRY | 6 | Feb 7, 2025 | clinicaltrials |
| NCT03212404 | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | active not recruiting | Phase 1 | 272 | Checkpoint Therapeutics, Inc.INDUSTRY | 9 | Feb 3, 2025 | clinicaltrials |
| NCT06758557 | A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 282 | Huabo Biopharm Co., Ltd.INDUSTRY | 1 | Jan 23, 2025 | clinicaltrials |
| NCT03667716 | COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. | completed | Phase 1 | 121 | Compugen LtdINDUSTRY | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06681870 | A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors | withdrawn | Phase 1 | 0 | Astellas Pharma Global Development, Inc.INDUSTRY | 0 | Jan 15, 2025 | clinicaltrials |
| NCT02630823 | MK-3475 Immunotherapy in Endometrial Carcinoma | completed | Phase 1 | 10 | Washington University School of MedicineOTHER | 1 | Jan 3, 2025 | clinicaltrials |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | terminated | Phase 1 / Phase 2 | 15 | Aminex Therapeutics, Inc.INDUSTRY | 2 | Dec 24, 2024 | clinicaltrials |
| NCT04660929 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | unknown | Phase 1 | 48 | Carisma Therapeutics IncINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT03345485 | Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.(EDO-S101) | completed | Phase 1 / Phase 2 | 71 | Mundipharma Research LimitedINDUSTRY | 5 | Oct 21, 2024 | clinicaltrials |
| NCT04652076 | GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab(GYNET) | active not recruiting | Phase 1 / Phase 2 | 240 | NETRIS PharmaINDUSTRY | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06620029 | BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer | not yet recruiting | Phase 1 / Phase 2 | 27 | BioMimetix JV, LLCINDUSTRY | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06614751 | A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway | not yet recruiting | Phase 1 | 112 | Danatlas Pharmaceuticals Co., LtdINDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT05655598 | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | withdrawn | Phase 1 | 0 | Brown UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05001282 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) | terminated | Phase 1 / Phase 2 | 79 | Elucida OncologyINDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06531486 | A Study of XS-02 Capsules in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 96 | NovaOnco Therapeutics Co., Ltd.INDUSTRY | 0 | Aug 1, 2024 | clinicaltrials |
| NCT02020707 | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers | completed | Phase 1 | 43 | Mayo ClinicOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT04570839 | COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. | completed | Phase 1 / Phase 2 | 48 | Compugen LtdINDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT03752398 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)(DUET-3) | completed | Phase 1 | 198 | Xencor, Inc.INDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
| NCT05538572 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | completed | Phase 1 | 22 | Prelude TherapeuticsINDUSTRY | 2 | Jul 1, 2024 | clinicaltrials |
| NCT03629756 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | completed | Phase 1 | 48 | Arcus Biosciences, Inc.INDUSTRY | 2 | May 24, 2024 | clinicaltrials |
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT02164461 | Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer | completed | Phase 1 | 12 | Advaxis, Inc.INDUSTRY | 1 | May 20, 2024 | clinicaltrials |
| NCT04823065 | 4FMFES-PET Imaging of Endometrial and Ovarian Cancers | completed | Phase 1 / Phase 2 | 53 | Centre de recherche du Centre hospitalier universitaire de SherbrookeOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT05107739 | A Study of DeTIL-0255 in Adults With Advanced Malignancies | terminated | Phase 1 | 5 | Nurix Therapeutics, Inc.INDUSTRY | 1 | May 3, 2024 | clinicaltrials |
| NCT04586335 | Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. | terminated | Phase 1 | 24 | Haihe Biopharma Co., Ltd.INDUSTRY | 3 | Mar 21, 2024 | clinicaltrials |
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 109 | NextCure, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT04780217 | Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 42 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Mar 4, 2024 | clinicaltrials |
| NCT02730923 | Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)(VICTORIA) | unknown | Phase 1 / Phase 2 | 72 | Centre Leon BerardOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT04149691 | Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies | unknown | Phase 1 | 42 | Celon Pharma SAINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT03454451 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | completed | Phase 1 | 117 | Corvus Pharmaceuticals, Inc.INDUSTRY | 2 | Dec 21, 2023 | clinicaltrials |
| NCT04474184 | Development of a New Early Detection Test to Reduce Racial Disparities in Endometrial Cancer (EC) Death Rates | completed | Phase 1 | 33 | Mayo ClinicOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04602117 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer | withdrawn | Phase 1 | 0 | QuantumLeap Healthcare CollaborativeOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05332483 | Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer(MA-EEC) | terminated | Phase 1 | 5 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 3, 2023 | clinicaltrials |
| NCT05498597 | AMT-151 in Patients With Selected Advanced Solid Tumours | unknown | Phase 1 | 30 | Multitude Therapeutics Inc.INDUSTRY | 2 | Oct 19, 2023 | clinicaltrials |
| NCT02988817 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 306 | GenmabINDUSTRY | 6 | Aug 1, 2023 | clinicaltrials |
| NCT01686256 | Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer | completed | Phase 1 | 12 | EndocyteINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04631731 | Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity(ICEMELT) | unknown | Phase 1 / Phase 2 | 200 | Western Sydney Local Health DistrictOTHER | 1 | Jun 1, 2023 | clinicaltrials |
Data updated 22 days agoSource updated May 28, 2025source: clinicaltrials